The global Pharmacokinetics Services Market is expanding steadily due to increasing drug discovery activities, growing biologics development, and rising outsourcing among pharmaceutical and biotechnology companies. Pharmacokinetics services support the evaluation of absorption, distribution, metabolism, and excretion (ADME) during preclinical and clinical drug development. Contract research organizations are increasingly investing in advanced bioanalytical technologies, AI-driven pharmacokinetic modeling, automated testing, and high-throughput analytical platforms to improve study efficiency and regulatory compliance.

According to Fortune Business Insights, the global pharmacokinetics services market was valued at USD 1.25 billion in 2025 and is projected to grow from USD 1.35 billion in 2026 to USD 2.40 billion by 2034, exhibiting a CAGR of 7.51% during the forecast period.

Why is the Pharmacokinetics Services Market Growing?

The rising need for specialized drug-development and bioanalytical services is a major factor supporting market growth. Pharmaceutical and biotechnology companies increasingly outsource pharmacokinetic studies to specialized CROs to access advanced laboratory infrastructure, scientific expertise, regulatory support, and scalable testing capabilities. More than 63% of pharmaceutical companies globally outsource at least part of their pharmacokinetic and bioanalytical testing activities to external providers.

Pharmacokinetics services are increasingly used for:

• ADME studies

• Bioavailability studies

• Drug metabolism studies

• Drug-drug interaction analysis

• Toxicology support

• Pharmacodynamic analysis

• Biomarker analysis

• Population pharmacokinetic modeling

• Clinical pharmacology

• Biologics characterization

The expansion of oncology, neurology, immunology, rare-disease, biosimilar, and precision-medicine pipelines is creating additional demand for specialized pharmacokinetic services.

Key Market Trends Shaping Industry Growth

Increasing Adoption of AI-Driven Pharmacokinetic Modeling

Artificial intelligence and machine learning are increasingly being incorporated into pharmacokinetic research. These technologies can assist with modeling drug absorption, metabolism, interactions, dosage optimization, and therapeutic-response prediction.

Fortune Business Insights highlights growing adoption of AI-driven pharmacokinetic modeling and machine-learning-based drug interaction analysis across modern drug-development workflows.

Growing Outsourcing of Bioanalytical Studies

Pharmaceutical and biotechnology companies are increasingly outsourcing pharmacokinetic and bioanalytical studies to CROs to reduce internal infrastructure requirements and accelerate development timelines.

CROs are expanding laboratory capacity, regulatory expertise, analytical capabilities, and integrated research services to serve this growing demand.

Expansion of Advanced LC-MS Technologies

Advanced liquid chromatography-mass spectrometry (LC-MS) and high-resolution mass spectrometry are becoming increasingly important for sensitive pharmacokinetic analysis.

More than 49% of newly established bioanalytical laboratories globally now include advanced LC-MS and high-resolution mass spectrometry capabilities for pharmacokinetic testing.

Increasing Demand for Biologics and Cell Therapy Evaluation

The growing development of biologics, monoclonal antibodies, peptide therapeutics, RNA-based medicines, gene therapies, and cell therapies is creating demand for specialized pharmacokinetic evaluation.

Service providers are developing capabilities for complex therapeutics where conventional analytical methodologies may not be sufficient.

Growth of Physiologically Based Pharmacokinetic Modeling

Physiologically based pharmacokinetic modeling is increasingly being used to optimize dosage design and assess drug behavior across different patient populations.

These models can help drug developers make more informed decisions during development and potentially reduce clinical-trial risks.

Market Dynamics

Driver: Rising Outsourcing of Drug Development and Bioanalytical Studies

Growing outsourcing is one of the strongest drivers of the Pharmacokinetics Services Market. Pharmaceutical and biotechnology companies are increasingly using CROs because specialized providers offer advanced laboratory infrastructure, experienced scientists, regulatory expertise, and scalable analytical capabilities.

More than 63% of pharmaceutical companies globally outsource at least part of their pharmacokinetic and bioanalytical testing. This trend is particularly important for oncology, neurology, immunology, and rare-disease development programs.

Restraint: High Complexity of Biologics and Regulatory Compliance

Advanced biologics, gene therapies, peptide therapeutics, and other complex molecules require specialized analytical methodologies and highly trained personnel.

More than 41% of small and mid-sized CROs report difficulties associated with maintaining advanced instrumentation and regulatory certification requirements. Biological sample variability, lengthy studies, and limited standardization across emerging therapeutic modalities can further increase operational complexity.

Opportunity: Expansion of Precision Medicine and Biologics Development

Precision medicine and biologics development are creating significant opportunities for pharmacokinetic service providers.

Nearly 38% of active clinical-stage biologics programs require advanced pharmacokinetic modeling and biomarker analysis support. Service providers are investing in AI-driven simulation platforms, cloud-based analytics, and advanced analytical technologies to serve increasingly complex therapeutic pipelines.

Challenge: Skilled Workforce Shortages and Data Integration

The shortage of experienced pharmacokinetic scientists, bioanalytical professionals, and regulatory specialists remains a major challenge.

More than 36% of global CROs report operational delays associated with shortages of experienced bioanalytical professionals and regulatory specialists. Integrating genomic, biomarker, clinical, and bioanalytical datasets also requires advanced computational infrastructure and specialized expertise.

For detailed market insights: https://www.fortunebusinessinsights.com/pharmacokinetics-services-market-116670

Market Segmentation Analysis

By Drug Type

Small Molecules Segment Dominates

Small molecules account for approximately 72% of the global Pharmacokinetics Services Market.

The large share is supported by extensive small-molecule drug-development pipelines and applications across oncology, cardiovascular, neurological, and anti-inflammatory therapies. More than 58% of active preclinical development programs globally involve small-molecule therapeutics requiring pharmacokinetic evaluation.

Growing utilization of AI-driven modeling, metabolism studies, bioavailability testing, and high-throughput LC-MS is further supporting this segment.

By Application

Small and Medium-sized Enterprises Segment

Small and medium-sized enterprises account for approximately 44% of the market by application.

Emerging biotechnology startups and specialty pharmaceutical companies increasingly rely on external providers because they often lack extensive in-house pharmacokinetic infrastructure.

More than 61% of small biotechnology companies globally outsource pharmacokinetic activities to reduce costs and accelerate development timelines.

Customized research packages, flexible pricing models, integrated regulatory support, and specialized bioanalytical services are helping CROs attract SME clients.

By End-use

Biotechnology and Pharmaceutical Companies Segment Leads

Biotechnology and pharmaceutical companies account for approximately 56% of the global Pharmacokinetics Services Market.

The segment is supported by high-volume drug-development pipelines and increasing investment in biologics, precision medicine, and complex therapeutics.

More than 67% of late-stage biologics programs globally utilize external pharmacokinetic service providers for regulatory and analytical support.

Regional Insights

North America Leads the Global Market

North America accounted for approximately 41% of the global Pharmacokinetics Services Market.

The region benefits from strong pharmaceutical innovation, extensive CRO networks, advanced bioanalytical infrastructure, and substantial clinical-trial activity. The U.S. remains the dominant contributor because of its large drug-development ecosystem and expanding biologics and precision-medicine programs.

The U.S. pharmacokinetics services market is supported by more than 6,500 active drug-development programs requiring pharmacokinetic and bioanalytical support, according to Fortune Business Insights.

Europe Holds a Significant Share

Europe accounted for approximately 30% of the global market. Strong pharmaceutical manufacturing capabilities, regulatory expertise, clinical research infrastructure, and growing biologics development are supporting market growth.

Germany represents approximately 28% of Europe's market, while the U.K. accounts for approximately 22%.

Asia Pacific Shows Strong Growth Potential

Asia Pacific accounted for approximately 22% of the global market and remains one of the fastest-expanding regions due to growing clinical research outsourcing, pharmaceutical manufacturing, and biotechnology investment.

Competitive Landscape

The global Pharmacokinetics Services Market is competitive, with leading contract research organizations and bioanalytical service providers focusing on advanced pharmacokinetic modeling, biologics testing, high-throughput screening, mass spectrometry, biomarker analysis, and decentralized clinical-trial support.

According to Fortune Business Insights, Charles River Laboratories International, Inc. held approximately 18% of the global market share, followed by PAREXEL International Corporation with approximately 15%.

Major Companies Operating in the Market

• Evotec AG

• Certara, L.P.

• Pacific BioLabs

• GVK Biosciences Private Limited

• Shanghai Medicilon Inc.

• Pharmaceutical Product Development, LLC

• Charles River Laboratories International, Inc.

• PAREXEL International Corporation

• Eurofins Scientific, Inc.

• Frontage Labs

• SGS SA

• LGC Limited

• Creative Bioarray

These companies are strengthening their capabilities through advanced bioanalytical infrastructure, AI-assisted pharmacokinetic modeling, biologics characterization, biomarker analysis, and integrated drug-development services.

Investment Analysis and Opportunities

The Pharmacokinetics Services Market is attracting significant investment because of increasing outsourcing of drug-development activities, growing biologics research, and rising demand for precision therapeutics analysis.

According to Fortune Business Insights, more than 45% of recent CRO investment activity focused on biologics characterization, peptide therapeutics testing, and decentralized clinical-trial capabilities. Service providers are also increasing investments in predictive analytics, physiologically based pharmacokinetic modeling, advanced mass spectrometry, and next-generation sequencing technologies.

Key Investment Opportunities

• AI-driven pharmacokinetic modeling

• Advanced LC-MS infrastructure

• High-throughput bioanalytical testing

• Biologics pharmacokinetics

• Peptide therapeutics

• RNA-based drug candidates

• Biomarker analysis

• Precision medicine research

• Decentralized clinical trials

• Cloud-based pharmacokinetic analytics

Emerging healthcare markets are also creating opportunities as pharmaceutical manufacturing, biotechnology investment, and clinical research outsourcing continue to expand.

New Product Development

Innovation remains an important competitive factor in the Pharmacokinetics Services Market. Service providers are developing advanced platforms designed to improve analytical sensitivity, automation, data integration, and predictive modeling.

Key areas of development include:

• AI-assisted pharmacokinetic simulation

• Cloud-based bioanalytical management systems

• Automated sample-preparation technologies

• Advanced LC-MS platforms

• Biomarker discovery systems

• Integrated PK/PD analysis

• Digital twin technologies

• Predictive dosage-selection platforms

• Drug-interaction modeling systems

• High-throughput pharmacokinetic screening

According to Fortune Business Insights, AI-assisted pharmacokinetic simulation platforms are increasingly being developed to predict drug absorption, metabolism, and toxicity outcomes. CROs are also introducing cloud-based systems that support real-time clinical-data integration and decentralized research operations.

Five Recent Industry Developments 2023–2025

According to Fortune Business Insights, notable developments include:

1. 2023: Certara, L.P. expanded AI-driven biosimulation capabilities supporting pharmacokinetic modeling and clinical-trial optimization.

2. 2023: Charles River Laboratories International, Inc. increased biologics testing capacity through laboratory automation and mass-spectrometry expansion.

3. 2024: Eurofins Scientific, Inc. introduced integrated bioanalytical and biomarker-analysis services for precision therapeutics development.

4. 2024: PAREXEL International Corporation expanded decentralized clinical-trial services integrated with pharmacokinetic monitoring platforms.

5. 2025: Shanghai Medicilon Inc. invested in high-throughput pharmacokinetic screening systems supporting oncology and biosimilar drug development.

Request Sample Report

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/pharmacokinetics-services-market-116670  

Future Outlook

The future of the Pharmacokinetics Services Market remains positive as pharmaceutical and biotechnology companies increasingly outsource specialized drug-development activities and invest in complex therapeutics.

According to Fortune Business Insights, the global market was valued at USD 1.25 billion in 2025 and is projected to grow from USD 1.35 billion in 2026 to USD 2.40 billion by 2034, exhibiting a CAGR of 7.51% during the forecast period.

Increasing Outsourcing of Pharmacokinetic Studies

More than 63% of pharmaceutical companies globally outsource at least part of their pharmacokinetic and bioanalytical testing activities to external service providers. This outsourcing trend is expected to remain a major growth driver as companies seek specialized expertise and scalable laboratory infrastructure.

Growing Demand for Biologics and Complex Therapeutics

The increasing development of monoclonal antibodies, peptides, RNA-based medicines, cell therapies, and gene therapies is creating demand for specialized pharmacokinetic services.

Nearly 38% of active clinical-stage biologics programs require advanced pharmacokinetic modeling and biomarker-analysis support.

Expansion of AI-Driven Pharmacokinetic Modeling

AI and machine learning are expected to play a larger role in pharmacokinetic modeling, drug-interaction analysis, dosage optimization, and clinical-trial planning.

The integration of predictive analytics with laboratory data can help researchers improve the efficiency of drug-development workflows.

Increasing Adoption of Advanced LC-MS

More than 49% of newly established bioanalytical laboratories globally now include advanced LC-MS and high-resolution mass-spectrometry capabilities for pharmacokinetic testing.

The continued development of highly sensitive analytical technologies is expected to support testing of increasingly complex therapeutic molecules.

Growth of Precision Medicine

Precision medicine is creating opportunities for pharmacokinetic services focused on individualized dosing and therapeutic-response prediction. Pharmaceutical companies are increasingly combining pharmacokinetic data with biomarkers, genomic information, and clinical data.

Expansion of Decentralized Clinical Trials

CROs are increasingly supporting decentralized clinical trials with cloud-based data systems, remote monitoring, and integrated pharmacokinetic analysis. This trend is expected to create additional demand for digital research infrastructure and distributed bioanalytical workflows.

Regional Growth Opportunities

North America held the largest regional share at approximately 41% in 2025, followed by Europe at 30%, Asia Pacific at 22%, and the Rest of the World at 7%.

North America

North America remains the leading market because of strong pharmaceutical innovation, extensive CRO networks, advanced bioanalytical infrastructure, and substantial clinical research activity.

The U.S. market is particularly important, with more than 6,500 active drug-development programs requiring pharmacokinetic and bioanalytical support services.

Europe

Europe accounted for approximately 30% of the global market. Strong pharmaceutical manufacturing capabilities, regulatory expertise, and biologics research are supporting demand.

Germany represents approximately 28% of Europe's market, while the U.K. accounts for approximately 22%.

Asia Pacific

Asia Pacific accounted for approximately 22% of the global market and remains one of the fastest-expanding regions because of clinical research outsourcing, pharmaceutical manufacturing, and biotechnology investments.

Japan represents approximately 24% of the Asia Pacific market, while China accounts for approximately 26%. More than 47% of newly established CRO laboratories in Asia Pacific now include advanced bioanalytical testing capabilities for complex therapeutics.

Rest of the World

The Rest of the World accounted for approximately 7% of the market. Latin America and the Middle East & Africa are witnessing growing demand for outsourced pharmacokinetic testing due to expanding pharmaceutical manufacturing, clinical research, generic-drug development, and biosimilar programs.

Overall, drug-development outsourcing, biologics research, AI-driven modeling, advanced LC-MS, precision medicine, and decentralized clinical trials are expected to remain the major growth areas for the Pharmacokinetics Services Market through 2034.

What’s Driving Japan’s Market? Discover the Latest  Pharmacokinetics Services Market  Insights